الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

physicians total care, inc. - insulin detemir (unii: 4ft78t86xv) (insulin detemir - unii:4ft78t86xv) - insulin detemir 14.2 mg in 1 ml - levemir is indicated to improve glycemic control in adults and children with diabetes mellitus. important limitations of use: - levemir is not recommended for the treatment of diabetic ketoacidosis. intravenous rapid-acting or short-acting insulin is the preferred treatment for this condition. levemir is contraindicated in patients with hypersensitivity to levemir or any of its excipients. reactions have included anaphylaxis [see warnings and precautions (5.4) and adverse reactions (6.1) ] pregnancy category c: in a fertility and embryonic development study, insulin detemir was administered to female rats before mating, during mating, and throughout pregnancy at doses up to 300 nmol/kg/day (3 times a human dose of 0.5 units/kg/day, based on plasma area under the curve (auc) ratio). doses of 150 and 300 nmol/kg/day produced numbers of litters with visceral anomalies. doses up to 900 nmol/kg/day (approximately 135 times a human dose of 0.5 units/kg/day based on auc ratio) were given to rabbits during organoge

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

dispensing solutions, inc. - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - insulin lispro 100 [iu] in 1 ml - humalog is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. humalog is contraindicated: - during episodes of hypoglycemia - in patients who are hypersensitive to humalog or to any of its excipients. pregnancy category b. all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. careful monitoring of glucose control is essential in these patients. therefore, female patients should be advised to tell their physicians

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

remedyrepack inc. - insulin aspart (unii: d933668qvx) (insulin aspart - unii:d933668qvx) - novolog is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. novolog is contraindicated: - during episodes of hypoglycemia [see warnings and precautions ( 5.3)] - in patients with hypersensitivity to novolog or one of its excipients, [see warnings and precautions ( 5.5)] risk summary available information from published randomized controlled trials with insulin aspart use during the second trimester of pregnancy have not reported an association with insulin aspart and major birth defects or adverse maternal or fetal outcomes [see data] . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see clinical considerations] . in animal reproduction studies, administration of subcutaneous insulin aspart to pregnant rats and rabbits during the period of organogenesis did not cause adverse developmental effects at

الفلبين - الإنجليزية - FDA (Food And Drug Administration)

novo nordisk pharmaceuticals (phils.) inc.; distributor: novo nordisk pharmaceuticals (phils.) inc. - biphasic insulin aspart 50 - suspension for injection (sc) [1 ml of suspension contains 100 units soluble insulin aspart/protamine-crystallized insulin aspar - 100 u/ml

كينيا - الإنجليزية - Pharmacy and Poisons Board

novo nordisk a/s novo alle dk-2880 bagsvaerd denmark - insulin degludec and insulin aspart - solution for injection - 70% insulin degludec / 30% insulin aspart,… - insulin degludec and insulin aspart

المملكة العربية السعودية - الإنجليزية - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novo nordisk, denmark - insulin degludec, insulin aspart - injection, solution - 100 iu/ml

المملكة العربية السعودية - الإنجليزية - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novo nordisk, denmark - insulin degludec,insulin aspart - solution for injection - 70,30 %, iu/ml,

كندا - الإنجليزية - Health Canada

novo nordisk canada inc - insulin degludec; liraglutide - solution - 100unit; 3.6mg - insulin degludec 100unit; liraglutide 3.6mg - insulins

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

intervet ireland limited - insulin - suspension for injection - 40 international unit(s)/millilitre - insulin (pork) - cats, dogs - hormone

الاتحاد الأوروبي - الإنجليزية - EMA (European Medicines Agency)

novo nordisk a/s - insulin degludec - diabetes mellitus - drugs used in diabetes - treatment of diabetes mellitus in adults.